Tumorigenicity assessments of Per.C6 cells and of an Ad5-vectored HIV-1 vaccine produced on this continuous cell line.

Autor: Ledwith BJ; Department of Safety Assessment, Merck Research Laboratories, Merck & Co., Inc., West Point, Pennsylvania 19486-0004, USA. brian_ledwith@merck.com, Lanning CL, Gumprecht LA, Anderson CA, Coleman JB, Gatto NT, Balasubramanian G, Farris GM, Kemp RK, Harper LB, Barnum AB, Pacchione SJ, Mauer KL, Troilo PF, Brown ER, Wolf JJ, Lebronl JA, Lewis JA, Nichols WW

Publikováno v: Developments in biologicals [Dev Biol (Basel)] 2006; Vol. 123, pp. 251-63; discussion 265-6.